Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Validation of a prognostic model for predicting larynx preservation outcome (TALK score) in a Southern European population.
Marruecos-Querol J, Rubió-Casadevall J, Lozano A, Buxó M, Puigdemont M, Linares I, Planas I, Vayreda J, Cirauqui B, Taberna M, Quiroga V, Tobed M, Borés A, Recalde S, Saigi M, Felip E, Eraso A, Mesía R. Marruecos-Querol J, et al. Among authors: rubio casadevall j. Clin Transl Oncol. 2023 Aug;25(8):2384-2392. doi: 10.1007/s12094-023-03121-9. Epub 2023 Mar 21. Clin Transl Oncol. 2023. PMID: 36943650
Temporal trends of incidence and survival of sarcoma of digestive tract including Gastrointestinal Stromal Tumours (GIST) in two areas of the north-east of Spain in the period 1981-2005: a population-based study.
Rubió-Casadevall J, Borràs JL, Carmona C, Ameijide A, Osca G, Vilardell L, Izquierdo A, Galceran J, Marcos-Gragera R. Rubió-Casadevall J, et al. Clin Transl Oncol. 2014 Jul;16(7):660-7. doi: 10.1007/s12094-013-1131-0. Epub 2013 Nov 19. Clin Transl Oncol. 2014. PMID: 24248893
Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study.
Mesía R, Garcia-Saenz JA, Lozano A, Pastor M, Grau JJ, Martínez-Trufero J, Lambeaz J, Martínez-Galán J, Mel JR, González B, Vázquez S, Mañós M, Taberna M, Cirauqui B, Del Barco E, Casado E, Rubió-Casadevall J, Rodríguez-Jaráiz A, Cruz JJ; Spanish Head And Neck Cancer Cooperative Group (Study TTCC-2007/02). Mesía R, et al. Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):473-480. doi: 10.1016/j.ijrobp.2016.11.016. Epub 2016 Nov 17. Int J Radiat Oncol Biol Phys. 2017. PMID: 28011050 Clinical Trial.
Population-based risk assessment of second primary cancers following a first head and neck cancer: patterns of association and difficulties of its analysis.
Rubió-Casadevall J, Galceran J, Ameijide A, Puigdemont M, Llauradó L, Marruecos J, Izquierdo A, Carulla M, Borràs JL, Marcos-Gragera R, Gumà J. Rubió-Casadevall J, et al. Clin Transl Oncol. 2021 Apr;23(4):788-798. doi: 10.1007/s12094-020-02470-z. Epub 2020 Aug 19. Clin Transl Oncol. 2021. PMID: 32815088
Oncogenic driver mutations predict outcome in a cohort of head and neck squamous cell carcinoma (HNSCC) patients within a clinical trial.
Fernández-Mateos J, Pérez-García J, Seijas-Tamayo R, Mesía R, Rubió-Casadevall J, García-Girón C, Iglesias L, Carral Maseda A, Adansa Klain JC, Taberna M, Vazquez S, Gómez MA, Del Barco E, Ocana A, González-Sarmiento R, Cruz-Hernández JJ. Fernández-Mateos J, et al. Sci Rep. 2020 Oct 6;10(1):16634. doi: 10.1038/s41598-020-72927-2. Sci Rep. 2020. PMID: 33024167 Free PMC article.
Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study.
Martínez-Trufero J, Lozano Borbalas A, Pajares Bernad I, Taberna Sanz M, Ortega Izquierdo E, Cirauqui Cirauqui B, Rubió-Casadevall J, Plana Serrahima M, Ponce Ortega JM, Planas Toledano I, Caballero J, Marruecos Querol J, Iglesias Docampo L, Lambea Sorrosal J, Adansa JC, Mesía Nin R; Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC). Martínez-Trufero J, et al. Clin Transl Oncol. 2021 Aug;23(8):1666-1677. doi: 10.1007/s12094-021-02567-z. Epub 2021 Apr 19. Clin Transl Oncol. 2021. PMID: 33876416 Clinical Trial.
Population-based analysis of the prevalence of BRAF mutation in patients diagnosed with cutaneous melanoma and its significance as a prognostic factor.
Rubió-Casadevall J, Carbó-Bagué A, Puigdemont M, Osca-Gelis G, Oliveras G, Vilar-Coromina N, Ferrer-Fabrega B, Urban A, Llobet-Roma M, Martín-Romero F, Perez-Bueno F, Marcos-Gragera R. Rubió-Casadevall J, et al. Eur J Dermatol. 2021 Oct 1;31(5):616-622. doi: 10.1684/ejd.2021.4136. Eur J Dermatol. 2021. PMID: 34789445
41 results